Stockscreener 앱 받기
67.96
2.04%
1.36
시간 외 거래:
67.96
전일 마감가:
$66.60
열려 있는:
$67.75
하루 거래량:
5.41M
Relative Volume:
0.97
시가총액:
$210.75B
수익:
$51.21B
순이익/손실:
$6.50B
주가수익비율:
32.59
EPS:
2.085
순현금흐름:
$6.76B
1주 성능:
+3.96%
1개월 성능:
+3.99%
6개월 성능:
-13.66%
1년 성능:
+2.13%
1일 변동 폭
$67.59
$68.38
1주일 범위
$65.03
$68.38
52주 변동 폭
$60.47
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
67.96 | 210.75B | 51.21B | 6.50B | 6.76B | 2.085 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - GlobeNewswire Inc.
ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming DeadlinesAZN - PR Newswire
AstraZeneca PLC ADR rises Tuesday, outperforms market - MarketWatch
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Yahoo Finance UK
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer - BioPharma Dive
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
2025-01-21 | AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca PLC (NASDAQ:AZN) Holdings Lifted by Brookmont Capital Management - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by ZWJ Investment Counsel Inc. - MarketBeat
Investors who lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class ActionAZN - GuruFocus.com
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - Markets Insider
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Yahoo Finance
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo - News & Insights
2025-01-20 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - PR Newswire
AstraZeneca gets first US approval for cancer treatment Datroway - ShareCast
AstraZeneca Plc Datroway approved in the US for metastatic breast cancer - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Oak Ridge Investments LLC - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
Professional Advisory Services Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Position Cut by Boston Common Asset Management LLC - MarketBeat
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector (NASDAQ:AZN) - Seeking Alpha
Procyon Advisors LLC Has $2.21 Million Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
23,847 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Empirical Asset Management LLC - MarketBeat
US FDA approves AstraZeneca's drug for breast cancer - Reuters.com
AstraZeneca, Daiichi Win FDA Approval for Breast Cancer Drug - Bloomberg
2025-01-17 | Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline - Benzinga
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
AstraZeneca rises Friday, still underperforms market - MarketWatch
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - Benzinga
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
AstraZeneca changes management of its China unit (AZN:NASDAQ) - Seeking Alpha
Faruqi & Faruqi Reminds AstraZeneca Investors of the - GlobeNewswire
AstraZeneca lymphoma drug gets expanded U.S. approval (AZN) - Seeking Alpha
AstraZeneca overhauls management of its China division, FT reports -January 17, 2025 at 09:12 am EST - Marketscreener.com
AstraZeneca overhauls management of its scandal-hit China division - Financial Times
Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Calquence Wins FDA Approval for Mantle Cell Lymphoma - TipRanks
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - Investing.com
Ritholtz Wealth Management Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA grants full approval for AstraZeneca's Calquence - The Pharma Letter
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Pharmaceutical Technology
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
AstraZeneca drug for rare blood cancer gets US regulatory green light - Proactive Investors USA
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):